MedCity News

APRIL 24, 2025

Contraline released promising new trial data showing that its male contraceptive gel has demonstrated safety and efficacy in the first two trial participants to reach the two-year mark. The company is aiming to earn the products FDA approval by the end of 2028, according to CEO Kevin Eisenfrats.

Safety 165

Safety FDA 165

European Pharmaceutical Review

JANUARY 23, 2025

For instance, patent expiries are set to wipe out $300 billion in revenues by 2028. With growing emergence of AI into 2025, the first part of the year saw the US Food and Drug Administration (FDA) issue draft recommendations on AI, which are set to address the safety, effectiveness or quality of drugs or biological products.

Pharma 59

Pharma Food and Drug Administration Pharmaceutical Government 59

Pharmaceutical Technology

DECEMBER 11, 2022

Due to the rarity of the disease, no FDA-approved therapy exists specifically for RT, and these patients are treated using regimens derived from the DLBCL treatment paradigm and other small-scale clinical trials. In the pirtobrutinib safety cohort, only 2.6% of patients discontinued treatment due to adverse events.

FDA 59

FDA Patients Safety Pharmaceutical 59

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Medico Reach

OCTOBER 17, 2022

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Pharmaceutical Technology

OCTOBER 28, 2022

The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. billion and $812 million in 2028. Further plans in the making.

Training 64

Training Marketing Competition FDA 64

Pharmaceutical Representative Training

JANUARY 29, 2025

These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition. The Cost-Saving Alternative: What are Biosimilars?

Marketing 52

Marketing Healthcare Healthcare Physicians 52